Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225115536> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4225115536 abstract "Bleomycin, a chemotherapy agent that inhibits synthesis of DNA, has been increasingly utilized in sclerotherapy for patients with vascular malformations. A serious long-term risk of intravenous bleomycin is dose-dependent interstitial pneumonitis. Little is known about absorption and circulating levels of bleomycin when used in sclerotherapy for patients with vascular malformations. This is an Institutional Review Board (IRB)-approved prospective study on patients receiving bleomycin sclerotherapy in the management of vascular malformations. Depending on the type of vascular malformation, bleomycin was administered either in the lumen or interstitial space of the involved lesion. A bleomycin assay measured serum bleomycin plasma concentrations versus time at seven intervals following treatment. Pharmacokinetic parameters were obtained for each participant and included peak plasma concentration (Cmax ), time to reach peak plasma concentration (Tmax ), volume of distribution (Vd ), elimination half-life (t1/2 ), the volume of plasma cleared of the drug per unit time (CL), and total systemic exposure area under the curve (AUC). Fifteen patients were enrolled (5: lymphatic, 4: venous, 6: arteriovenous malformations). Bleomycin was administered interstitially (IS) in 11 patients and intraluminal (IL) in four; median age of 13 years (range: 2-67). Pharmacokinetic analysis revealed terminal elimination half-life (t1/2λz ) of 88.51 (±23.09) and 111.61 (±37.75) minutes for the IS and IL groups, respectively. Vd was 4.86 L (±6.74) and 1.55 L (±0.54) for the IS and IL groups, respectively. AUC was 53.9 (±23.45) and 129.17 (±93.57) mg min/L for the IS and IL groups, respectively. There were no statistically significant differences in t1/2λz , Vd , or AUC parameters between groups. Bleomycin is absorbed systemically when used as a sclerosant for vascular malformations when injected either IS or IL." @default.
- W4225115536 created "2022-05-01" @default.
- W4225115536 creator A5023870621 @default.
- W4225115536 creator A5033695026 @default.
- W4225115536 creator A5040460552 @default.
- W4225115536 creator A5041625514 @default.
- W4225115536 creator A5050062777 @default.
- W4225115536 creator A5072202968 @default.
- W4225115536 creator A5073134373 @default.
- W4225115536 date "2022-04-28" @default.
- W4225115536 modified "2023-10-18" @default.
- W4225115536 title "Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations" @default.
- W4225115536 cites W1514716841 @default.
- W4225115536 cites W2010500972 @default.
- W4225115536 cites W2081406906 @default.
- W4225115536 cites W2099297962 @default.
- W4225115536 cites W2108363413 @default.
- W4225115536 cites W2112830398 @default.
- W4225115536 cites W2327668702 @default.
- W4225115536 cites W2408827397 @default.
- W4225115536 cites W2792898947 @default.
- W4225115536 doi "https://doi.org/10.1002/pbc.29733" @default.
- W4225115536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35484878" @default.
- W4225115536 hasPublicationYear "2022" @default.
- W4225115536 type Work @default.
- W4225115536 citedByCount "1" @default.
- W4225115536 countsByYear W42251155362022 @default.
- W4225115536 crossrefType "journal-article" @default.
- W4225115536 hasAuthorship W4225115536A5023870621 @default.
- W4225115536 hasAuthorship W4225115536A5033695026 @default.
- W4225115536 hasAuthorship W4225115536A5040460552 @default.
- W4225115536 hasAuthorship W4225115536A5041625514 @default.
- W4225115536 hasAuthorship W4225115536A5050062777 @default.
- W4225115536 hasAuthorship W4225115536A5072202968 @default.
- W4225115536 hasAuthorship W4225115536A5073134373 @default.
- W4225115536 hasConcept C112705442 @default.
- W4225115536 hasConcept C126322002 @default.
- W4225115536 hasConcept C126894567 @default.
- W4225115536 hasConcept C139254425 @default.
- W4225115536 hasConcept C141071460 @default.
- W4225115536 hasConcept C22979827 @default.
- W4225115536 hasConcept C2776232574 @default.
- W4225115536 hasConcept C2776694085 @default.
- W4225115536 hasConcept C2778230777 @default.
- W4225115536 hasConcept C71924100 @default.
- W4225115536 hasConcept C76318530 @default.
- W4225115536 hasConcept C90924648 @default.
- W4225115536 hasConceptScore W4225115536C112705442 @default.
- W4225115536 hasConceptScore W4225115536C126322002 @default.
- W4225115536 hasConceptScore W4225115536C126894567 @default.
- W4225115536 hasConceptScore W4225115536C139254425 @default.
- W4225115536 hasConceptScore W4225115536C141071460 @default.
- W4225115536 hasConceptScore W4225115536C22979827 @default.
- W4225115536 hasConceptScore W4225115536C2776232574 @default.
- W4225115536 hasConceptScore W4225115536C2776694085 @default.
- W4225115536 hasConceptScore W4225115536C2778230777 @default.
- W4225115536 hasConceptScore W4225115536C71924100 @default.
- W4225115536 hasConceptScore W4225115536C76318530 @default.
- W4225115536 hasConceptScore W4225115536C90924648 @default.
- W4225115536 hasFunder F4320310362 @default.
- W4225115536 hasIssue "8" @default.
- W4225115536 hasLocation W42251155361 @default.
- W4225115536 hasLocation W42251155362 @default.
- W4225115536 hasOpenAccess W4225115536 @default.
- W4225115536 hasPrimaryLocation W42251155361 @default.
- W4225115536 hasRelatedWork W1949576538 @default.
- W4225115536 hasRelatedWork W1986613524 @default.
- W4225115536 hasRelatedWork W2054172655 @default.
- W4225115536 hasRelatedWork W2083862627 @default.
- W4225115536 hasRelatedWork W2125585793 @default.
- W4225115536 hasRelatedWork W2156704820 @default.
- W4225115536 hasRelatedWork W2169014630 @default.
- W4225115536 hasRelatedWork W2421630916 @default.
- W4225115536 hasRelatedWork W2972921306 @default.
- W4225115536 hasRelatedWork W4290199464 @default.
- W4225115536 hasVolume "69" @default.
- W4225115536 isParatext "false" @default.
- W4225115536 isRetracted "false" @default.
- W4225115536 workType "article" @default.